Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Pemetrexed in Resectable NSCLC
NCT00226577Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate. Started Feb 2004; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00226577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226577.